Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder

Neuropsychobiology

Volumn 54, Issue 4, 2007, Pages 201-207

  Schmitt, Laurent ^a   Tonnoir, Brigitte ^b   Arbus, Christophe ^a  

^a Toulouse University   (France)

^b H LUNDBECK A S   (Denmark)

Author keywords

Citalopram, intravenous; Escitalopram, safety, efficacy; Major depressive disorder; Treatment switch

Indexed keywords

ALIMEMAZINE TARTRATE; ALPRAZOLAM; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CITALOPRAM; CLONAZEPAM; CLORAZEPATE DIPOTASSIUM; CYAMEMAZINE; ESCITALOPRAM; FLUOXETINE; HEPTAMINOL; HYDROXYZINE; LEVOTHYROXINE SODIUM; LORMETAZEPAM; MEPROBAMATE; OXAZEPAM; PRAZEPAM; PSYCHOTROPIC AGENT; VENLAFAXINE; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOPICLONE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; ASTHENIA; BACKACHE; BRONCHOPHARYNGITIS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PHARYNGITIS; PRIORITY JOURNAL; RATING SCALE; REMISSION; SOMNOLENCE; SUICIDE ATTEMPT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERTIGO; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34147126925     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100368     Document Type: Article

References (27)

1. Faravelli C, Pallanti S: Clomipramine by different routes of administration: short- and long-term efficacy and predictors of clinical outcome. Psychopharmacol Bull 1987;23:459-463.
2. Luscombe DK, Wright J: Plasma level studies of clomipramine and desmethylclomipramine following intravenous infusions of clomipramine in depressed patients. Postgrad Med J 1977;53(suppl 4):88-96.
3. Laux G, König W, Baumann P: Le traitement des dépressions par perfusions intraveineuses - Manuel clinique et pratique. Paris, Acanthe, 1998.
4. Moukaddam NJ, Hirschfeld RMA: Intravenous antidepressants: a review. Depress Anxiety 2004;19:1-9.
5. Baumann P, Nil R, Bertschy G, et al: A double blind double-dummy study of citalopram comparing infusion versus oral administration. J Affect Disord 1998;49:203-210.
6. Bouchard J, Strub N, Nil R: Citalopram and viloxazine in the treatment of depression by means of a slow drop infusion: a double-blind comparative trial. J Affect Disord 1997;46:51-58.
7. Guelfi JD, Strub N, Loft H: Efficacy of intravenous citalopram compared with oral citalopram for severe depression: safety and efficacy data from a double-blind, double-dummy trial. J Affect Disord 2000:58:201-209.
8. Kasper S, Müller-Spahn F: Intravenous antidepressant treatment: focus on citalopram. Eur Arch Psychiatry Clin Neurosci 2002;252:105-109.
9. Hyttel J, Bogeso KP, Perregaard J, et al: The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992;88:157-160.
10. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C: Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 2004;174:163-176.
11. Burke WJ, Gergel I, Bose A: Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63;331-336.
12. Lepola UM, Loft H, Reines EH: Escitalopram (10-20 g/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-217.
13. Wade A, Lemming OM, Hedegaard KB: Escitalopram 10 mg/day is effective and well tolerated in placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95-102.
14. Auquier P, Robitail S, Llorca PM, Rive B: Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatry Clin Pract 2003;7:259-268.
15. Lepola U, Wade A, Andersen HF: Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004;19:149-155.
16. Azorin JM, Llorca PM, Despiegel N, Verpillat P: Traitement des épisodes dépressifs sévères: escitalopram est plus efficace que citalopram. Encéphale 2004;30:158-166.
17. The American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4 (DSM-IV). Washington, American Psychiatric Association, 1994 (French translation, Manuel diagnostique et statistique des troubles mentaux. Paris, Masson, 1996, p 377).
18. Lecrubier Y, Sheehan DV, Weiller E, et al: The Mini International Neuropsychiatric Interview (MINI) - A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 1997;12:224-231.
19. Montgomery S, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
20. Guy W: ECDEU assessment manual for psychopharmacology, rev. US dept Health, Education and Welfare publication (ADM) 76-338. Bethesda, National Institute of Mental Health, 1976.
21. Lepape A, Lecomte T: Prévalence et prise en charge médicale de la dépression en 1996-1997. Bulletin d'information en économie de la santé no 21. Paris, CREDES, 1999.
22. Bech P, Tanghoj P, Cialdella P, Andersen HF, Pedersen AG: Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 2004;7:283-290.
23. Gruwez B, Gury C, Poirier MF, Bouvet O, Gerard A, Bourdel MC, Bayle FJ, Olie JP: Comparison of two assessment tools of antidepressant side-effects: UKU scale versus spontaneous notification. Encephale 2004;30:425-432.
24. Lindstrom E, Lewander T, Malm U, Malt UF, Lublin H, Ahlfors UG: Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia: clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry 2001;55(suppl 44):5-69.
25. Kasper S, Lemming OM, de Swart H: Escitalopram in the long-term treatment of major depressive disorder in elderly patients. Neuropsychobiology 2006;54:152-159.
26. Wade A, Lemming OM, Hedegaard KB: Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95-102.
27. Rapaport MH, Bose A, Zheng H: Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004;65:44-49.